Intravitreal Fluocinolone Acetonide 0.19 mg Implant in a Patient with Resistant Blau Syndrome: A Case Report
Introduction: Blau syndrome is a progressive disease with an unknown etiology and pathogenesis. It can cause severe damage, especially in the eye with severe involvement. Case Presentation: A six-year-old female was referred to us complaining about blurry vision and floaters in both eyes for 1 year....
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karger Publishers
2024-01-01
|
| Series: | Case Reports in Ophthalmology |
| Subjects: | |
| Online Access: | https://beta.karger.com/Article/FullText/535984 |
| _version_ | 1797306810575618048 |
|---|---|
| author | Khushi Saigal Arash Maleki |
| author_facet | Khushi Saigal Arash Maleki |
| author_sort | Khushi Saigal |
| collection | DOAJ |
| description | Introduction: Blau syndrome is a progressive disease with an unknown etiology and pathogenesis. It can cause severe damage, especially in the eye with severe involvement. Case Presentation: A six-year-old female was referred to us complaining about blurry vision and floaters in both eyes for 1 year. She had been diagnosed with Blau syndrome and Blau syndrome-associated anterior uveitis. Her best-corrected visual acuity in the right and left eyes was 20/70 and 20/80, respectively. Slit-lamp exam revealed faint bilateral band keratopathy along with 1+ anterior chamber cells and posterior synechia 360° in both eyes. During dilated fundoscopy, 2+ haze in the media was observed, along with swollen and hyperemic disc OU. Based on changes in optical coherence tomography, fluorescein angiography, and indocyanine green angiography, she was diagnosed with panuveitis and retinal vasculitis. Given her complicated history, we decided to proceed with an intravitreal fluocinolone acetonide 0.19 mg implant implantation in both eyes. During the 1-month follow-up visit, vitreous haze, retinal vasculitis, and active choroiditis were resolved. At 6-month follow-up visit, no changes were observed compared to the 1-month follow-up visit. Conclusion: In cases of Blau syndrome that display resistance to systemic immunomodulatory therapies, the inclusion of local treatments, such as the intravitreal fluocinolone acetonide 0.19 mg implant, should be considered as an adjunctive therapeutic option. |
| first_indexed | 2024-03-08T00:46:13Z |
| format | Article |
| id | doaj.art-88a9f296b5d04b388f1f392096844043 |
| institution | Directory Open Access Journal |
| issn | 1663-2699 |
| language | English |
| last_indexed | 2024-03-08T00:46:13Z |
| publishDate | 2024-01-01 |
| publisher | Karger Publishers |
| record_format | Article |
| series | Case Reports in Ophthalmology |
| spelling | doaj.art-88a9f296b5d04b388f1f3920968440432024-02-15T07:38:01ZengKarger PublishersCase Reports in Ophthalmology1663-26992024-01-01151637010.1159/000535984535984Intravitreal Fluocinolone Acetonide 0.19 mg Implant in a Patient with Resistant Blau Syndrome: A Case ReportKhushi Saigal0Arash Maleki1College of Medicine, University of Florida, Gainesville, FL, USADepartment of Ophthalmology, University of Florida, Gainesville, FL, USAIntroduction: Blau syndrome is a progressive disease with an unknown etiology and pathogenesis. It can cause severe damage, especially in the eye with severe involvement. Case Presentation: A six-year-old female was referred to us complaining about blurry vision and floaters in both eyes for 1 year. She had been diagnosed with Blau syndrome and Blau syndrome-associated anterior uveitis. Her best-corrected visual acuity in the right and left eyes was 20/70 and 20/80, respectively. Slit-lamp exam revealed faint bilateral band keratopathy along with 1+ anterior chamber cells and posterior synechia 360° in both eyes. During dilated fundoscopy, 2+ haze in the media was observed, along with swollen and hyperemic disc OU. Based on changes in optical coherence tomography, fluorescein angiography, and indocyanine green angiography, she was diagnosed with panuveitis and retinal vasculitis. Given her complicated history, we decided to proceed with an intravitreal fluocinolone acetonide 0.19 mg implant implantation in both eyes. During the 1-month follow-up visit, vitreous haze, retinal vasculitis, and active choroiditis were resolved. At 6-month follow-up visit, no changes were observed compared to the 1-month follow-up visit. Conclusion: In cases of Blau syndrome that display resistance to systemic immunomodulatory therapies, the inclusion of local treatments, such as the intravitreal fluocinolone acetonide 0.19 mg implant, should be considered as an adjunctive therapeutic option.https://beta.karger.com/Article/FullText/535984blau syndromechoroiditisfluocinolone acetonide implantimmunomodulatory therapyuveitis |
| spellingShingle | Khushi Saigal Arash Maleki Intravitreal Fluocinolone Acetonide 0.19 mg Implant in a Patient with Resistant Blau Syndrome: A Case Report Case Reports in Ophthalmology blau syndrome choroiditis fluocinolone acetonide implant immunomodulatory therapy uveitis |
| title | Intravitreal Fluocinolone Acetonide 0.19 mg Implant in a Patient with Resistant Blau Syndrome: A Case Report |
| title_full | Intravitreal Fluocinolone Acetonide 0.19 mg Implant in a Patient with Resistant Blau Syndrome: A Case Report |
| title_fullStr | Intravitreal Fluocinolone Acetonide 0.19 mg Implant in a Patient with Resistant Blau Syndrome: A Case Report |
| title_full_unstemmed | Intravitreal Fluocinolone Acetonide 0.19 mg Implant in a Patient with Resistant Blau Syndrome: A Case Report |
| title_short | Intravitreal Fluocinolone Acetonide 0.19 mg Implant in a Patient with Resistant Blau Syndrome: A Case Report |
| title_sort | intravitreal fluocinolone acetonide 0 19 mg implant in a patient with resistant blau syndrome a case report |
| topic | blau syndrome choroiditis fluocinolone acetonide implant immunomodulatory therapy uveitis |
| url | https://beta.karger.com/Article/FullText/535984 |
| work_keys_str_mv | AT khushisaigal intravitrealfluocinoloneacetonide019mgimplantinapatientwithresistantblausyndromeacasereport AT arashmaleki intravitrealfluocinoloneacetonide019mgimplantinapatientwithresistantblausyndromeacasereport |